Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) shares traded up 10.7% during mid-day trading on Wednesday . The stock traded as high as $0.8994 and last traded at $0.8073. 3,104,766 shares traded hands during trading, an increase of 61% from the average session volume of 1,927,646 shares. The stock had previously closed at $0.7292.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cypherpunk Technologies in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Sell".
View Our Latest Research Report on Cypherpunk Technologies
Cypherpunk Technologies Price Performance
The company has a market capitalization of $72.64 million, a PE ratio of 11.53 and a beta of -0.22. The company has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.91.
Institutional Investors Weigh In On Cypherpunk Technologies
Institutional investors have recently modified their holdings of the stock. Sequoia Financial Advisors LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $56,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $121,000. Millennium Management LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $37,000. LPL Financial LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $38,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth $59,000. 30.46% of the stock is owned by hedge funds and other institutional investors.
About Cypherpunk Technologies
(
Get Free Report)
Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.
DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cypherpunk Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cypherpunk Technologies wasn't on the list.
While Cypherpunk Technologies currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
